Volume 4, Issue 3, Fall 2025

View Volume 4, Issue 3, Fall 2025

New Developments in the Front‑line Treatment of Advanced Stage Classic Hodgkin Lymphoma: A Canadian Perspective
Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies
Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor
Rational Use of Immunoglobulin in Adult Patients with Secondary Hypogammaglobulinemia in the Setting of Hematologic Malignancy: A Canadian Perspective

Published: 2025-12-08

Full Issue

Articles

New Developments in the Front‑line Treatment of Advanced Stage Classic Hodgkin Lymphoma: A Canadian Perspective

Jowon L. Kim, MD, Kerry J. Savage, MD

5–17
- PDF (en)
- PDF (fr)
Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies

Christopher Lemieux, MD, FRCPC, DRCPC

19–22
- PDF (en)
- PDF (fr)
Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor

Jesse Shustik, MD, FRCPC

24–35
- PDF (en)
- PDF (fr)
Rational Use of Immunoglobulin in Adult Patients with Secondary Hypogammaglobulinemia in the Setting of Hematologic Malignancy: A Canadian Perspective

Oksana Prokopchuk-Gauk, MD, FRCPC, DRCPSC, Kathryn Webert, MD, MSc, FRCPC, Jennifer Grossman, MD, FRCPC

37–54
- PDF (en)
- PDF (fr)